Berlin - Delayed Quote EUR

Applied Therapeutics Inc (2UV.BE)

0.5630

-0.0170

(-2.93%)

As of 8:30:14 PM GMT+1. Market Open.

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industriesNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmace

GlobeNewswire 10 days ago

APLT
Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against other penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global Advisors’ […]

Insider Monkey 23 days ago

APLT

^RUT

^GSPC
Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Applied Therapeutics, Inc. (NASDAQ:APLT) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million […]

Insider Monkey 25 days ago

APLT
Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Adrian Alexandru, representing all similarly affected investors, has filed a federal securities class-action lawsuit against Applied Therapeutics (NASDAQ:APLT), alleging the company violated federal securities laws. The lawsuit claims that the company provided misleading information about its clinical trials and failed to disclose key adverse facts, causing significant financial losses for shareholders. Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbust

Benzinga last month

APLT
Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr

GlobeNewswire last month

RVPH

RVPHW

VSTM
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

APLT
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

Applied Therapeutics (APLT) faces uncertainty after the US Food and Drug Administration rejected the

PREMIUM
MT Newswires last month

APLT
Company News for Dec 2, 2024

Companies in The News Are: APLT,TGT,WMT,AAPL

Zacks last month

APLT

WMT

TGT
Applied Therapeutics CRL a ‘major setback,’ says William Blair

William Blair says Applied Therapeutics (APLT)’ complete response letter from the FDA for govorestat for the treatment of galactosemia is “unexpected and disappointing.” Given the lack of information in the CRL, it is unclear what the path forward for govorestat in galactosemia is and whether an additional clinical trial will be necessary for approval in this indication, the analyst tells investors in a research note. The firm says that while the rejection is a “major setback,” there is a possib

TipRanks 2 months ago

APLT
Applied Therapeutics downgraded to Sector Perform from Outperform at RBC

RBC Capital analyst Brian Abrahams downgraded Applied Therapeutics (APLT) to Sector Perform from Outperform with a price target of $4, down from $12. The complete response letter for govorestat in galactosemia is disappointing and “creates significant uncertainties” around a future path forward for the drug in that indication, the analyst tells investors in a research note. The firm still sees “meaningful residual value” from sorbitol dehydrogenase deficiency where a new drug application submiss

TipRanks 2 months ago

APLT
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%

The company plans to request a meeting with the FDA to discuss potential resubmission

GuruFocus.com 2 months ago

APLT
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks 2 months ago

BBIO

APLT

SAVAW
Top Midday Decliners

Applied Therapeutics (APLT) late Wednesday said the US Food and Drug Administration has issued a com

PREMIUM
MT Newswires 2 months ago

APLT

RMBL
Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks were higher in Friday afternoon trading, with the NYSE Health Care Index and the

PREMIUM
MT Newswires 2 months ago

APLT

EVT.DE
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says

Applied Therapeutics' (APLT) lead drug candidate, govorestat, likely faces "significant" uncertainty

PREMIUM
MT Newswires 2 months ago

APLT
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Barrons.com 2 months ago

APLT
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug

Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, causing its shares to crater Friday.

Investopedia 2 months ago

APLT
Applied Therapeutics' Govorestat Faces Unclear Regulatory Path After FDA Rejection, RBC Says

Applied Therapeutics' (APLT) lead drug govorestat faces "significant uncertainties" around a regulat

PREMIUM
MT Newswires 2 months ago

APLT
RBC downgrades Applied Therapeutics as FDA rejects Govorestat, hacks price target

Investing.com -- RBC Capital Markets downgraded Applied Therapeutics Inc (NASDAQ:APLT) stock to "sector perform" from "outperform” citing increased risks after the U.S. Food and Drug Administration (FDA) rejected the company’s application for its experimental drug govorestat to treat galactosemia.

Investing.com 2 months ago

APLT
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA

Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.

Zacks 2 months ago

APLT

Performance Overview

Return	2UV.BE	S&P 500
YTD	-30.67%	+2.58%
1-Year	-79.03%	+23.04%
3-Year	-76.74%	+36.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Applied Therapeutics Inc (2UV.BE)

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?

Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

Company News for Dec 2, 2024

Applied Therapeutics CRL a ‘major setback,’ says William Blair

Applied Therapeutics downgraded to Sector Perform from Outperform at RBC

FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

Top Midday Decliners

Sector Update: Health Care Stocks Rise in Afternoon Trading

Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment After FDA Rejection, RBC Says

Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.

Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug

Applied Therapeutics' Govorestat Faces Unclear Regulatory Path After FDA Rejection, RBC Says

RBC downgrades Applied Therapeutics as FDA rejects Govorestat, hacks price target

APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA

Performance Overview